Human lung microRNA profiling in pulmonary arterial hypertension secondary to congenital heart defect

Pediatric Pulmonology

Volumn 50, Issue 12, 2015, Pages 1214-1223

  Ma, Kai ^a   Zhao, Qian ^a   Chen, Weidan ^b   Zhang, Hao ^a   Li, Shoujun ^a   Pan, Xiangbin ^a   Chen, Qiuming ^a  

^a FUWAI HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

congenital heart defects; microRNA; molecular biology; Notch1; pulmonary arterial hypertension

Indexed keywords

MICRORNA; MICRORNA 27B; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; MIRN27 MICRORNA, HUMAN; NOTCH1 PROTEIN, HUMAN;

ARTICLE; BIOINFORMATICS; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HEART SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG ARTERY PRESSURE; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SYSTEMIC PULMONARY SHUNT; UPREGULATION; VALIDATION PROCESS; COMPLICATION; GENETICS; HEART DEFECTS, CONGENITAL; HYPERTENSION, PULMONARY; INFANT; LUNG; METABOLISM;

CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; LUNG; MALE; MICROARRAY ANALYSIS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH1; UP-REGULATION;

EID: 84955216808     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23181     Document Type: Article

References (40)

1. Berger RM, Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J 2000; 21: 17-27.
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F,. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF,. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
4. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF,. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L1013-L1032.
5. Rabinovitch M, Pathobiology of pulmonary hypertension. Annu Rev Pathol 2007; 2: 369-399.
6. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N,. et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31.
7. Rosenzweig EB, Barst RJ,. Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery. Prog Cardiovasc Dis 2012; 55: 128-133.
8. Guo H, Weissman JS, Bartel DP,. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
9. Bartel DP, MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233.
10. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson R,. et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010; 30: 716-723.
11. Wenlei Li, Kai Ma, Sen Zhang, Hao Zhang, Jinping Liu, Xu Wang, Shoujun Li. Pulmonary MicroRNA Expression Profiling in an Immature Piglet Model of Cardiopulmonary Bypass-Induced Acute Lung Injury. Artif Organs. 2014 Oct 27. doi: 10.1111/aor.12387. [Epub ahead of print].
12. Heath D, Edwards JE,. The pathology of hypertensive pulmonary vascular disease: A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533-547.
13. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB,. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
14. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,. et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
15. Sethupathy P, Megraw M, Hatzigeorgiou AG,. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006; 3: 881-886.
16. Wang X, El Naqa,. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 2008; 24: 325-332.
17. Wang X, MiRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA 2008; 14: 1012-1017.
18. Bandyopadhyay S, Mitra R,. TargetMiner: microRNA target prediction with systematic identification of tissue-specific negative examples. Bioinformatics 2009; 25: 2625-2631.
19. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T,. MiRecords: An integrated resource for microRNA-target interactions. Nucleic acids research 2009; 37: D105-D110.
20. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM,. et al. MiRTarBase: A database curates experimentally validated microRNA-target interactions. Nucleic acids research 2011; 39: D163-D169.
21. Sethupathy P, Corda B, Hatzigeorgiou AG,. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 2006; 12: 192-197.
22. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S,. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101: 59-68.
23. Fukuda Y, Kawasaki H, Taira K,. Exploration of human miRNA target genes in neuronal differentiation. Nucleic Acids Symp Ser (Oxf) 2005; 49: 341-342.
24. Chan SY, Loscalzo J,. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44: 14-30.
25. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J,. et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208: 535-548.
26. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY,. et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: Results of a network bioinformatics approach. Circulation 2012; 125: 1520-1532.
27. Li S, Ran Y, Zhang D, Chen J, Li S, Zhu D,. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodeling by targeting Mst1. Biochem J 2013; 452: 281-291.
28. Gou D, Ramchandran R, Peng X, Yao L, Kang K, Sarkar J, Wang Z, Zhou G, Raj JU,. MiR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 2012; 303: L682-L691.
29. Urbich, Kuehbacher CA, Dimmeler S,. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-588.
30. Chen Y, Gorski DH,. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-1226.
31. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC,. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104: 1184-1191.
32. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, Erzurum SC, Aldred MA,. Altered MicroRNA processing in heritable pulmonary arterial hypertension: An important role for Smad-8. Am J Respir Crit Care Med 2011; Dec 15 184: 1400-1408.
33. Wang KC, Garmire LX, Young A, Nguyen P, Trinh A, Subramaniam S, Wang N, Shyy JY, Li YS, Chien S,. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci USA 2010; 107: 3234-3239.
34. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S,. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23-27-24 clusters. Proc Natl Acad Sci USA 2011; 108: 8287-8292.
35. Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt N, Podgrabinska S, Shiraishi K,. et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 2007; 117: 3369-3382.
36. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ,. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw-7 F-box protein. Proc Natl Acad Sci USA 2004; 101: 3338-3345.
37. Qiao L, Xie L, Shi K, Zhou T, Hua Y, Liu H,. Notch signaling change in pulmonary vascular remodeling in rats with pulmonary hypertension and its implication for therapeutic intervention. PLoS ONE 2012; 7: 51514.
38. Williams CK, Li JL, Murga M, Harris AL, Tosato G,. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107: 931-939.
39. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM,. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155: 411-419.
40. Taylor KL, Henderson AM, Hughes CC,. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and down-regulates VEGFR-2/KDR expression. Microvasc Res 2002; 64: 372-383.